Wpływ kompleksu 2-Atycyto i D-Rybozy na ból i przebieg kliniczny u pacjentów z fibromialgią
Wpływ kompleksu 2-Aticyto i D-Rybozy na ból, objawy i przebieg kliniczny u pacjentów z zespołem fibromialgii
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. Participants will be randomly assigned to receive either FibroThol or placebo, administered as 15 mL three times daily for 4 weeks, while continuing their existing treatment. Follow-up assessments will be performed at baseline, week 2, and week 4 using patient-reported symptom and function measures. The study aims to determine whether this supportive supplement provides additional benefit compared with placebo in patients with persistent symptoms despite standard therapy.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Fibromyalgia syndrome is a chronic condition associated with widespread pain, fatigue, sleep disturbance, and reduced quality of life. Although standard pharmacologic treatments such as pregabalin and duloxetine are commonly used, symptom control may remain incomplete in many patients. This study was designed to investigate whether adding a supplement containing 2-Aticyto Complex and D-ribose to ongoing standard treatment can improve clinical outcomes in adults with fibromyalgia syndrome.
This is a multicenter, randomized, double-blind, placebo-controlled clinical study. Adults aged 18 to 65 years with fibromyalgia syndrome, diagnosed according to the ACR 2016 criteria, followed for at least 1 year, and receiving pregabalin and/or duloxetine treatment for at least 3 months will be eligible for participation. Major exclusion criteria include rheumatologic disease, renal failure, hepatic failure, cardiovascular disease, diabetes or hypoglycemia, neurologic disease, use of other supplements, allergy to study product ingredients, inability to complete study procedures, or refusal to participate.
After eligibility assessment and informed consent, participants will be randomly assigned to one of two study groups: placebo plus ongoing standard treatment or FibroThol plus ongoing standard treatment. The study treatment will be administered orally at a dose of 15 mL three times daily for 4 weeks. Study visits and assessments will be performed at baseline, week 2, and week 4.
Outcome measures will include pain intensity, neuropathic pain, fibromyalgia-related functional status, fatigue, sleep quality, anxiety, and depression, assessed using validated clinical scales. Safety will be evaluated through adverse event monitoring during the study period.
A total of 200 participants will be enrolled, with 100 participants assigned to the FibroThol group and 100 participants assigned to the placebo group. The primary objective is to determine whether the addition of 2-Aticyto Complex and D-ribose to standard treatment provides additional benefit in reducing pain and improving symptoms and overall clinical course in patients with fibromyalgia syndrome.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Kubra Neslihan Kurt Oktay, MD
- Numer telefonu: +905352916609
- E-mail: drneslihankurt@gmail.com
Lokalizacje studiów
-
-
-
Istanbul, Turcja (Türkiye), 34480
- University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Fatih Bagcıer, MD
- Numer telefonu: +905442429042
- E-mail: bagcier_42@hotmail.com
-
Istanbul, Turcja (Türkiye), 34668
- University of Health Sciences, Sultan Abdulhamid Han Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Mustafa Hüseyin Temel, MD
- Numer telefonu: +905342714872
- E-mail: mhuseyintemel@gmail.com
-
Pod-śledczy:
- Emre Ata, MD
-
Istanbul, Turcja (Türkiye), 34732
- Erenkoy Physical Therapy and Rehabilitation Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Sefa Kurt, MD
- Numer telefonu: +905385159528
- E-mail: sefa.kurt@yahoo.com
-
Istanbul, Turcja (Türkiye), 34752
- University of Health Sciences, Fatih Sultan Mehmet Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Ozge Gulsum Illeez, MD
- Numer telefonu: +905326255684
- E-mail: ozgeilleez@gmail.com
-
-
Istanbul
-
Istanbul, Istanbul, Turcja (Türkiye), 34662
- University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
-
Kontakt:
- Kubra Neslihan Kurt Oktay, MD
- Numer telefonu: +905352916609
- E-mail: drneslihankurt@gmail.com
-
Pod-śledczy:
- Arzu Erbilici, MD
-
Pod-śledczy:
- Duygu Geler Kulcu, MD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Adults aged 18 to 65 years
- Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
- Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
- Receiving pregabalin and/or duloxetine treatment for at least 3 months
- Able to live independently in the community
- Literate and able to record symptoms and responses
- No cognitive dysfunction that would interfere with answering study questions
- Able and willing to provide informed consent
Exclusion Criteria:
- Rheumatologic disease
- Renal failure
- Hepatic failure
- Cardiovascular disease
- Hypoglycemia or diabetes mellitus
- Any neurologic disease (such as stroke, spinal cord injury, multiple sclerosis, or Parkinson's disease)
- Known allergy or hypersensitivity to any active or excipient component of the study syrup
- Use of any other dietary supplement or nutritional support product during the study period
- Pregnancy or lactation
- Active malignancy
- Active infection
- Severe psychiatric disease that may interfere with study participation or assessment
- Refusal to participate or inability to provide informed consent
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Komparator placebo: Placebo Plus Standard Treatment
Participants will receive matching placebo orally at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
A matching oral placebo syrup without active study ingredients. In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. The placebo contains deionized water, glycerol, sodium alginate, xanthan gum, steviol glycosides, raspberry flavor, pineapple flavor, strawberry flavor, and mint flavor. |
|
Eksperymentalny: FibroThol Plus Standard Treatment
Participants will receive FibroThol, an oral supplement containing 2-Aticyto Complex and D-ribose, at 15 mL three times daily for 4 weeks, in addition to their ongoing standard medical treatment with pregabalin and/or duloxetine. |
An oral dietary supplement containing 2-Aticyto Complex and D-ribose (marketed as FibroThol). In this study, participants will receive 15 mL orally three times daily for 4 weeks in addition to ongoing standard treatment with pregabalin and/or duloxetine. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Pain Intensity Measured by Numeric Rating Scale (NRS)
Ramy czasowe: Baseline, Week 2, and Week 4
|
Pain intensity will be assessed using the Numeric Rating Scale (NRS), an 11-point scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Neuropathic Pain Measured by DN4
Ramy czasowe: Baseline, Week 2, and Week 4
|
Neuropathic pain symptoms will be assessed using the Douleur Neuropathique 4 (DN4) questionnaire, with a total score range of 0 to 10. Higher scores indicate more neuropathic pain features, and a score of 4 or more suggests neuropathic pain. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Impact Questionnaire Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Fibromyalgia Participation Questionnaire Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Fatigue severity will be assessed using the Fatigue Severity Scale, a 9-item scale with a total score range of 9 to 63. Higher scores indicate greater fatigue severity. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Fatigue Severity Scale (FSS) Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Participation limitations will be assessed using the Fibromyalgia Participation Questionnaire, with transformed scale values ranging from 0 to 100. Higher scores indicate better participation and social functioning, so an increase from baseline reflects improvement. |
Baseline, Week 2, and Week 4
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Sleep quality will be assessed using the Pittsburgh Sleep Quality Index, with a global score range of 0 to 21. Higher scores indicate poorer sleep quality. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Depression Inventory Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Depressive symptoms will be assessed using the Beck Depression Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe depressive symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
|
Change in Beck Anxiety Inventory Score
Ramy czasowe: Baseline, Week 2, and Week 4
|
Anxiety symptoms will be assessed using the Beck Anxiety Inventory, a 21-item scale with a total score range of 0 to 63. Higher scores indicate more severe anxiety symptoms. Change from baseline will be compared between groups. |
Baseline, Week 2, and Week 4
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Kubra Neslihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
- Krzesło do nauki: Kubra Nesihan Kurt Oktay, MD, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Department of Physical Medicine and Rehabilitation
Publikacje i pomocne linki
Publikacje ogólne
- Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006 Nov;12(9):857-62. doi: 10.1089/acm.2006.12.857.
- Teitelbaum J, Jandrain J, McGrew R. Treatment of Chronic Fatigue Syndrome and Fibromyalgia with D-Ribose- An Open-label, Multicenter Study. The Open Pain Journal. 2012;5:32-37.
- Kerget F, Kerget B, Aksakal A, Kocak AO. Can 2-Aticyto Complex be an Effective Agent for Recovery of The Symptoms and Enhancing Laboratory Parameters in COVID-19 Patients? European Journal of Medical and Health Sciences. 2021;3(2):35-39. doi:10.24018/ejmed.2021.3.2.745.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Objawy neurologiczne
- Choroby układu mięśniowo-szkieletowego
- Choroby Układu Nerwowego
- Choroby mięśni
- Zaburzenia psychiczne
- Choroby nerwowo-mięśniowe
- Choroby reumatyczne
- Objawy behawioralne
- Zaburzenia snu i czuwania
- Zaburzenia snu, wewnętrzne
- Dyssomnie
- Stany patologiczne, oznaki i objawy
- Zachowanie
- Objawy i symptomy
- Ból
- Zaburzenia lękowe
- Fibromialgia
- Depresja
- Zaburzenia inicjacji i utrzymania snu
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- HNHAH-KAEK 2025/1
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data will not be shared. Aggregate results will be reported in publications and trial registry updates.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .